Related Experiment Video

Updated: May 23, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

MicroRNAs and Androgen Receptor 3' Untranslated Region: A Missing Link in Castration-resistant Prostate Cancer?

Kavleen Sikand1, Sailen Barik, Girish C Shukla

  • 1Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, Ohio.

Molecular and Cellular Pharmacology
|April 3, 2012
PubMed

Insights

Androgen receptor (AR) is key in prostate cancer. MicroRNAs (miRNAs) targeting AR may drive castration-resistant prostate cancer (CRPC), offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Androgen receptor (AR) is crucial in prostate cancer development and progression.
  • Prostate cancer transitions from androgen-dependent to castration-resistant prostate cancer (CRPC) through genetic and epigenetic alterations.
  • The molecular mechanisms underlying this transition remain incompletely understood, but AR's role is evident.

Purpose of the Study:

  • To explore the role of microRNAs (miRNAs) in targeting the androgen receptor (AR).
  • To discuss potential molecular pathways through which AR-targeting miRNAs contribute to CRPC pathogenesis.
  • To highlight miRNA-based modulation of AR as a novel therapeutic avenue for prostate cancer.

Main Methods:

  • Review of current literature on AR function in prostate cancer.
  • Discussion of miRNA biogenesis and mechanism of action (targeting 3' UTR of mRNA).
  • Analysis of potential pathways linking AR-targeting miRNAs to CRPC development.

Main Results:

  • MicroRNAs (miRNAs) can directly target and modulate androgen receptor (AR) function.
  • AR-targeting miRNAs are implicated in the progression of prostate cancer to castration-resistant forms.
  • These miRNAs likely influence AR expression and activity through post-transcriptional regulation.

Conclusions:

  • MicroRNAs (miRNAs) targeting the androgen receptor (AR) represent a significant factor in prostate cancer progression to CRPC.
  • Modulating AR expression via miRNAs offers a promising, novel therapeutic strategy.
  • Combination therapy involving miRNA modulation alongside existing treatments may be effective for prostate cancer.

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...